XENE biotech catalysts & pipeline

XENON PHARMACEUTICALS INC · Data as of 2026-09-08

Upcoming catalysts

azetukalner — NDA/BLA submission

Q3 2026

Xenon remains on track to submit its New Drug Application (NDA) for azetukalner in FOS in the third quarter of 2026, having completed a pre-NDA meeting with the U.S. Food and Drug Administration (FDA).

Source filing

XEN1120 — Full data

H2 2026

Phase 1 studies of novel Na V 1.7 (XEN1701) and K V 7 (XEN1120) candidates expected to complete H2 2026 to support Phase 2 proof-of-concept studies in pain

Source filing

XEN1701 — Full data

H2 2026

Phase 1 studies of novel Na V 1.7 (XEN1701) and K V 7 (XEN1120) candidates expected to complete H2 2026 to support Phase 2 proof-of-concept studies in pain

Source filing

azetukalner — Topline data

H1 2027

Enrollment is ongoing in the Phase 3 X-NOVA2 and X-NOVA3 studies evaluating azetukalner in patients with MDD, with topline data from X-NOVA2 expected in H1 2027.

Source filing

NBI-921355 — Initial data

2027

Data from the Phase 1b study are expected in 2027.

Source filing

Explore the free biotech catalyst calendar